About this trial
To assess the effect of 3 months of daily consumption of a postbiotic (inactivated lactic acid bacteria) Humiome® Post LB on stress measured by the Depression Anxiety Stress Scale-21 (DASS-21) adjusted on baseline in study participants when compared to placebo
Eligibility criteria
Qualifiers
Participant is male or female, 50-75 years of age, inclusive.
Participant has a Body Mass Index (BMI) of ≥18.5 kg/m2 to 32 kg/m2.
Participant is generally in good health, as per investigator's judgement at V1.
Participant has subjective mild to moderate memory complaints, as per investigator's judgement.
Disqualifiers
Participant has a history or presence of a psychiatric or neurologic disease including epilepsy, cerebrovascular disease, traumatic brain injury, dementia, Alzheimer's Disease, clinical depression, or other clinically significant psychiatric/neurologic condition that, in the opinion of the investigator, could interfere with the interpretation of the study results.
MMSE score at V1 < 21.
Chronic fatigue syndrome.
Women: elevated stress and/or anxiety levels clearly related to the (peri) menopause complaints, as per investigator judgement
Trial design
Treatments tested in this trial
- Humiome Post LB (Postbiotic)
- Placebo
Treatment groups
Sponsors and collaborators
dsm-firmenich Switzerland AG
Lead sponsor
Analyze & Realize
Collaborator